A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 7, 2014, Pages 1993-2004

  Prymula, Roman ^a,b   Esposito, Susanna ^c   Zuccotti, Gian Vincenzo ^c   Xie, Fang ^d   Toneatto, Daniela ^d   Kohl, Igor ^d   Dull, Peter M ^d  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF MILAN   (Italy)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

Antipyretics; Infants; Meningococcal; Serogroup B; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PARACETAMOL; PNEUMOCOCCUS VACCINE; 4CMENB VACCINE; ANTIPYRETIC AGENT;

ARTICLE; AUSTRALIA; BLOOD GROUP TYPING; CAUCASIAN; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; EUROPE; FEMALE; FEVER; HISPANIC; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE REACTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; PATHOLOGICAL CRYING; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SEROTYPE; SOMNOLENCE; URTICARIA; VACCINATION REACTION; VOMITING; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; NEISSERIA MENINGITIDIS;

ACETAMINOPHEN; ANTIPYRETICS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INFANT; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PROSPECTIVE STUDIES;

EID: 84908018914     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28666     Document Type: Article

References (27)

1. Crocetti M, Moghbeli N, Serwint J. Fever phobia revisited: have parental misconceptions about fever changed in 20 years? Pediatrics 2001; 107:1241-6; PMID:11389237; http://dx.doi.org/10.1542/peds.107.6.1241
2. Sullivan JE, Farrar HC; Section on Clinical Pharmacology and Therapeutics; Committee on Drugs. Fever and antipyretic use in children. Pediatrics 2011; 127:580-7; PMID:21357332; http://dx.doi.org/10.1542/peds.2010-3852
3. Centers for Disease Control (CDC). Pertussis immunization; family history of convulsions and use of antipyretics - supplementary ACIP statement. MMWR Morb Mortal Wkly Rep 1987; 36:281-2; PMID:3155353
4. Ipp MM, Gold R, Greenberg S, Goldbach M, Kupfert BB, Lloyd DD, Maresky DC, Saunders N, Wise SA. Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphtheria-pertussis-tetanus toxoids-polio vaccine. Pediatr Infect Dis J 1987; 6:721-5; PMID:3313232; http://dx.doi.org/10.1097/00006454-198708000-00005
5. Lewis K, Cherry JD, Sachs MH, Woo DB, Hamilton RC, Tarle JM, Overturf GD. The effect of prophylactic acetaminophen administration on reactions to DTP vaccination. Am J Dis Child 1988; 142:62-5; PMID:3277388
6. Jackson LA, Peterson D, Dunn J, Hambidge SJ, Dunstan M, Starkovich P, Yu O, Benoit J, Dominguez-Islas CP, Carste B, et al. A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants. PLoS One 2011; 6:e20102; PMID:21698100; http://dx.doi.org/10.1371/journal.pone.0020102
7. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, Lommel P, Kaliskova E, Borys D, Schuerman L. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374:1339-50; PMID:19837254; http://dx.doi.org/10.1016/S0140-6736(09)61208-3
8. Uhari M, Hietala J, Viljanen MK. Effect of prophylactic acetaminophen administration on reaction to DTP vaccination. Acta Paediatr Scand 1988; 77:747-51; PMID:3059756; http://dx.doi.org/10.1111/j.1651-2227.1988.tb10741.x
9. Long SS, Deforest A, Smith DG, Lazaro C, Wassilak GF. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990; 85:294-302; PMID:2304782
10. Prymula R, Habib A, Franc¸ois N, Borys D, Schuerman L. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine 2013; 31:2080-8; PMID:23391599; http://dx.doi.org/10.1016/j.vaccine.2013.01.044
11. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30(Suppl 2):B26-36; PMID:22178525; http://dx.doi.org/10.1016/j.vaccine.2011.12.032
12. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51:1127-37; PMID:20954968; http://dx.doi.org/10.1086/656741
13. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010; 29:e71-9; PMID:20844462
14. Gossger N, Snape MD, Yu L-M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant meningococcal serogroup B vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573-82; PMID:22318278; http://dx.doi.org/10.1001/jama.2012.85
15. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381:825-35; PMID:23324563; http://dx.doi.org/10.1016/S0140-6736(12)61961-8
16. Esposito S, Roman Prymula R, Zuccotti GV, Kittel C, Toneatto D, Kohl I, Dull P. A phase 2 randomised controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II): effects of variations of the OMV and protein content on immunogenicity and reactogenicity. Hum Vaccin Immunother 2014; 10:2015-23; http://dx.doi.org/10.4161/hv.29218
17. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(Suppl 2):B112-6; PMID:19464093; http://dx.doi.org/10.1016/j.vaccine.2009.04.065
18. Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher MC, Gold MS, Hartman K, Heininger U, Hoet B, Jefferson T, Khuri-Bulos N, et al.; Brighton Collaboration Methods Working Group. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine 2009; 27:2289-97; PMID:19061929; http://dx.doi.org/10.1016/j.vaccine.2008.11.035
19. Chen RT, Clark TA, Halperin SA. The yin and yang of paracetamol and paediatric immunisations. Lancet 2009; 374:1305-6; PMID:19837236; http://dx.doi.org/10.1016/S0140-6736(09)61802-X
20. Heininger U, Sänger R, Jacquet J-M, Schuerman L; DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25:1055-63; PMID:17049692; http://dx.doi.org/10.1016/j.vaccine.2006.09.060
21. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20; PMID:20410516; http://dx.doi.org/10.1056/NEJMra0906357
22. Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-7; PMID:3108388
23. Sullivan JE, Farrar HC; Section on Clinical Pharmacology and Therapeutics; Committee on Drugs. Fever and antipyretic use in children. Pediatrics 2011; 127:580-7; PMID:21357332; http://dx.doi.org/10.1542/peds.2010-3852
24. Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nøkleby H, Rosenqvist E, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-6; PMID:1682541; http://dx.doi.org/10.1016/0140-6736(91)91961-S
25. Holst J, Martin D, Arnold R, Huergo CC, Oster P, O'Hallahan J, Rosenqvist E. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27(Suppl 2):B3-12; PMID:19481313; http://dx.doi.org/10.1016/j.vaccine.2009.04.071
26. O'Hallahan J, McNicholas A, Galloway Y, O'Leary E, Roseveare C. Delivering a safe and effective strainspecific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009; 122:48-59; PMID:19322255
27. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26; PMID:4023479; http://dx.doi.org/10.1002/sim.4780040211